Fig. 4: Betulin synergizes Sorafenib’s effect on HCC s.c. tumor growth. | Cell Death & Disease

Fig. 4: Betulin synergizes Sorafenib’s effect on HCC s.c. tumor growth.

From: SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity

Fig. 4

a MHCC97-H cells were injected into nude mice subcutaneously. At day 6, mice started receiving vehicle control, or the indicated concentrations of Sorafenib, or 2 mg/kg Betulin or the indicated concentration of Sorafenib + 2 mg/kg Betulin orally every other day 10 times. At day 21 post treatment, mice were killed and tumors were obtained (N = 10). b Quantitative results of tumor volume and tumor weight from a

Back to article page